CEL-SCI Corporation raised $10.8 million in a debt financing offering led by ThinkEquity to fund the continued development of Multikine and for working capital.
PUBLIC · CVMJul 29, 2024
Amount Raised
$10.8 Million
Round Type
Debt Financing
ViennaBiotechnologyHealthcareHealth Care
Investors
Think Equity
Description
CEL-SCI Corporation announced the closing of its best-efforts offering of 10,845,000 shares of common stock for gross proceeds of $10,845,000. The company intends to use the net proceeds from the offering for the development of Multikine and general corporate purposes.
Who to call at CEL-SCI Corporation, and when
A new round usually means CEL-SCI Corporation is about to hire and buy. The teams that reach out first get the meeting.
An alert the day CEL-SCI Corporation raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at CEL-SCI Corporation, from your own LinkedIn network
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Company Information
Company
CEL-SCI Corporation
Location
Vienna, Illinois, United States
About
CEL-SCI is a clinical-stage biotechnology company focused on finding the best way to activate the immune system to fight cancer and infectious diseases. The Company’s lead investigational therapy Multikine completed a pivotal Phase 3 clinical trial involving head and neck cancer, for which the Company has received Orphan Drug Status from the FDA. The Company will be commencing a confirmatory trial for Multikine, with enrollment expected to begin in Q4 2024. The Company has operations in Vienna, Virginia, and near Baltimore, Maryland.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment CEL-SCI Corporation raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
ViennaBiotechnologyHealthcareHealth Care